Healthcare · NIFTY 500
Biocon Limited
₹370.95 +2.90 (+0.79%) Updated 12 Nov, 8:49 pm IST
Today
- Open
- ₹368.05
- Prev close
- ₹368.05
- Day high
- ₹372.20
- Day low
- ₹365.10
- Volume
- 29.63 L
- Value traded
- ₹109.29 Cr
- Upper circuit
- ₹381.30
- Lower circuit
- ₹359.10
- 52W high
- ₹447.15
- 52W low
- ₹318.40
- 1 month
- +4.31%
- 6 months
- -6.49%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 | 4,389 |
| Other income | 566 | 48.6 | 1,135 | 32.5 | 34.8 | 36.9 | 79.7 | 93.0 | 117 | 52.5 | 54.5 | 34.5 |
| Total income | 4,519 | 3,966 | 4,567 | 3,623 | 3,856 | 4,454 | 4,022 | 4,389 | 4,290 | 4,569 | 4,391 | 4,423 |
| Raw material | 1,403 | 1,478 | 860 | 1,009 | 1,293 | 1,114 | 1,224 | 1,368 | 1,327 | 1,359 | 1,424 | 1,669 |
| Purchases | 33.3 | -0.1 | 409 | 49.1 | 85.5 | 83.5 | 837 | 135 | 168 | 223 | 382 | 311 |
| Employee cost | 721 | 742 | 755 | 790 | 788 | 811 | 833 | 888 | 875 | 912 | 916 | 892 |
| Other expenses | 1,074 | 930 | 874 | 933 | 922 | 1,055 | 955 | 1,025 | 1,125 | 1,185 | 1,105 | 1,145 |
| Total expenses | 3,708 | 3,635 | 3,454 | 3,551 | 3,718 | 3,988 | 3,925 | 4,205 | 4,065 | 4,241 | 4,249 | 4,362 |
| Operating profit | 948 | 907 | 652 | 711 | 770 | 1,099 | 749 | 824 | 540 | 940 | 834 | 824 |
| OPM % | 24.0% | 23.2% | 19.0% | 19.8% | 20.1% | 24.9% | 19.0% | 19.2% | 12.9% | 20.8% | 19.2% | 18.8% |
| Finance cost | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 | 240 |
| Depreciation | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 | 564 |
| Exceptional items | 21.2 | -8.8 | 32.0 | 26.0 | 18.1 | 20.4 | — | -11.9 | -293 | -80.4 | -13.5 | -6.7 |
| Profit before tax | 832 | 322 | 1,146 | 98.4 | 156 | 487 | 96.9 | 171 | -67.8 | 248 | 128 | 54.8 |
| Tax | 54.9 | 96.1 | 284 | 71.3 | 74.8 | 27.4 | 7.7 | 38.5 | -16.0 | 48.9 | -9.2 | -1.9 |
| Net profit | 753 | 223 | 862 | 27.1 | 81.1 | 459 | 89.2 | 133 | -51.8 | 199 | 137 | 56.7 |
| Profit to shareholders | 660 | 136 | 660 | -16.0 | 25.1 | 345 | 31.4 | 84.5 | 144 | 126 | 141 | 41.3 |
| EPS (₹) | 5.51 | 1.13 | 5.51 | -0.13 | 0.21 | 2.87 | 0.26 | 0.65 | 1.07 | 0.79 | 0.87 | 0.25 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,514 | 6,367 | 7,106 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 |
| Other income | 144 | 161 | 255 | 213 | 376 | 866 | 1,208 | 343 |
| Total expenses | 4,639 | 5,381 | 6,226 | 7,096 | 10,195 | 14,000 | 14,680 | 16,419 |
| Employee cost | 1,165 | 1,459 | 1,741 | 1,880 | 2,181 | 2,664 | 3,144 | 3,508 |
| Operating profit | 1,588 | 1,671 | 1,665 | 1,859 | 2,220 | 3,287 | 3,263 | 3,052 |
| OPM % | 28.8% | 26.2% | 23.4% | 22.7% | 19.9% | 22.3% | 21.4% | 18.0% |
| Finance cost | 70.9 | 64.9 | 57.7 | 67.6 | 419 | 974 | 897 | 990 |
| Depreciation | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,957 |
| Profit before tax | 1,214 | 1,215 | 1,147 | 1,190 | 1,064 | 1,609 | 1,887 | 448 |
| Tax | 212 | 315 | 222 | 212 | 254 | 227 | 457 | 79.1 |
| Tax rate % | 17.5% | 25.9% | 19.3% | 17.8% | 23.9% | 14.1% | 24.2% | 17.7% |
| Net profit | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 |
| Profit to shareholders | 905 | 748 | 741 | 648 | 463 | 1,023 | 1,013 | 386 |
| Net margin % | 16.4% | 11.8% | 10.4% | 7.9% | 4.1% | 6.9% | 6.6% | 2.3% |
| EPS (₹) | 15.20 | 6.30 | 6.19 | 5.42 | 3.87 | 8.54 | 8.46 | 2.82 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 17,867 | 19,784 | 21,644 | 34,032 | 34,843 |
| Long-term borrowings | 15,291 | 12,932 | 12,405 | 10,746 | 11,027 |
| Short-term borrowings | 2,480 | 2,797 | 5,350 | 4,078 | 4,083 |
| Total borrowings | 17,771 | 15,730 | 17,756 | 14,825 | 15,110 |
| Current liabilities | 8,511 | 15,359 | 14,334 | 14,069 | 14,731 |
| Fixed assets (PPE) | 7,535 | 7,418 | 8,708 | 9,473 | 9,766 |
| Inventories | 4,244 | 4,944 | 4,931 | 6,086 | 7,145 |
| Trade receivables | 3,573 | 6,231 | 5,488 | 5,987 | 6,059 |
| Cash & equivalents | 1,324 | 1,234 | 3,227 | 2,417 | 2,204 |
| Current assets | 12,334 | 15,179 | 16,286 | 17,180 | 18,010 |
| Total assets | 52,043 | 56,071 | 58,797 | 63,651 | 65,280 |
| Debt / equity | 0.99 | 0.80 | 0.82 | 0.44 | 0.43 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,177 | 1,853 | 2,954 | 4,061 | 1,994 |
| Cash from investing | -1,699 | -14,282 | -1,005 | -234 | -2,082 |
| Cash from financing | 242 | 13,049 | -2,333 | -1,854 | -924 |
| Spent on fixed assets | -1,698 | -1,596 | -1,681 | -2,137 | -1,798 |
| Free cash flow | -521 | 257 | 1,273 | 1,925 | 196 |
| Net cash flow | -280 | 619 | -383 | 1,973 | -1,012 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (30 Sep 2026)
- Promoter & group
- 44.68%
- Public (FIIs, mutual funds, retail…)
- 55.14%
- Employee trusts
- 0.19%
- Promoter change, last quarter
- 0.00 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Re 0.50 Per Share
- Dividend - Rs 0.50 Per Share
- Dividend - Re 0.50 Per Share
- Dividend - Rs 1.50 Per Share
- Dividend - Rs 0.50 Per Share
- Dividend - Rs 0.50 Per Share
- Bonus 1:1
- Dividend- Re 1 Per Share
Board meetings
- BIOCON LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial res…
- the financial results for the period ended September 30, 2026
- BIOCON LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2026 to inter-alia consider and approve the Unaudited Financial res…
- the financial results for the period ended Jun 30, 2026
- Fund raising.
Filings with NSE
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Resignation of Director/KMP/SMP
- General Updates
- Investor Presentation
Latest news
BIOCON Outlook for the WeekEquitypandit · 8 Nov, 1:30 pmBiocon share price rises nearly 6% despite 52% dip in Q2 profitBusiness Standard · 5 Nov, 1:29 pmBIOCON Stock Price and Chart — NSE:BIOCONTradingView · 15 Aug, 12:30 pmBiocon shares rise 3% after stake sale in Rs 635-cr block deal; company eyes $1 billion biosimilars...Moneycontrol.com · 9 Sep, 12:30 pmBiocon Share Price Near Yearly Low: Fundamentals and P/EUnivest · 21 Oct, 12:30 pmBiocon Shares Jump 8% After Mylan Launches Rs 3,481 Crore Block DealHDFC Sky · 14 Jul, 12:30 pmWhy Biocon Share Price is RisingEquitymaster · 14 Jul, 12:30 pmBiocon shares jump 8% after likely block deal; here is what is known so farUpstox · 13 Jul, 12:30 pmAbout
About Biocon Limited
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Biocon Limited
- NSE symbol
- BIOCON
- BSE scrip code
- 532523
- ISIN
- INE376G01013
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 7 Apr 2004
- Face value
- ₹5 per share
- Market lot
- 1 share
- Shares issued
- 162.96 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Shreehas Tambe
- Chair
- Kiran Mazumdar-Shaw
- Headquarters
- Bengaluru
- Registered address
- 20th KM Hosur Road, Electronic City, Bengaluru – 560 100, Karnataka, India
- Founded
- 1978
- Employees
- 5,261
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- biocon.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.